Phenotype Image Detail

Image

Caption

(B) Intradermal injection of an anti-Kit antibody (ACK2) decreases the number of melanocytes in the epidermis of Csnk1a1^tm1.1Ybn/Csnk1a1^tm1.1Ybn Tg(KRT14-cre/ERT)20Efu/0 (SKO) mice at days 7 and 14 compared with vehicle-treated SKO mice. (E) Oral treatment with imatinib for 3 weeks cancels the CK1alpha ablation-induced eumelanization and epidermal thickening. Phenotype examination reveals hypopigmentation in imatinib-treated mice compared with vehicle-treated mice at day 28. Histopathology shows thinning of the epidermis with decreased eumelanin and melanocytes in the epidermis in imatinib-treated mice at day 28. Data are shown as means SD; *P < 0.05, **P < 0.01, and ***P < 0.001. (Scale bars, 50 um in B and 100 um in E.)

Copyright

This image is from Chang CH, Proc Natl Acad Sci U S A 2017 Sep 19;114(38):E8035-E8044. Copyright 2017 National Academy of Sciences, U.S.A. J:253611

Associated Alleles

Symbol	Name
Csnk1a1^tm1.1Ybn	casein kinase 1, alpha 1; targeted mutation 1.1, Yinon Ben-Neriah
Tg(KRT14-cre/ERT)20Efu	transgene insertion 20, Elaine Fuchs

Associated Genotypes

Allelic Composition	Genetic Background
Csnk1a1^tm1.1Ybn/Csnk1a1^tm1.1Ybn Tg(KRT14-cre/ERT)20Efu/0	involves: 129S1/Sv * 129X1/SvJ * CD-1